UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer

Diabetes, obesity & metabolism, 2015-06, Vol.17 (6), p.523-532

2015

Volltextzugriff (PDF)

Cardiovascular safety of sulphonylureas: over 40years of continuous controversy without an answer

Diabetes, obesity & metabolism, 2015-06, Vol.17 (6), p.523-532

2015

Volltextzugriff (PDF)

How have pharmacists in different practice settings integrated prescribing privileges into practice in Alberta? A qualitative exploration

Journal of clinical pharmacy and therapeutics, 2014-08, Vol.39 (4), p.390-398

2014

Volltextzugriff (PDF)

206TiP SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma

Annals of oncology, 2023-11, Vol.34, p.S1554

2023

Volltextzugriff (PDF)

Endogenous Group Formation via Unproductive Costs

The Review of economic studies, 2013-10, Vol.80 (4 (285)), p.1215-1236

2013

Volltextzugriff (PDF)

169P Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)

Annals of oncology, 2024-06, Vol.35, p.S77-S78

2024

Volltextzugriff (PDF)

CO70 Matching Adjusted Indirect Comparison (MAIC) of Single Tremelimumab Regular Interval Durvalumab (STRIDE) Versus Atezolizumab with Bevacizumab (A+B) for the Treatment of Unresectable Hepatocellular Carcinoma (UHCC)

Value in health, 2023-06, Vol.26 (6), p.S27-S27

2023

Volltextzugriff (PDF)

167P Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Annals of oncology, 2024-06, Vol.35, p.S75-S76

2024

Volltextzugriff (PDF)

947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

Annals of oncology, 2024-09, Vol.35, p.S656-S656

2024

Volltextzugriff (PDF)

79P Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study

Annals of oncology, 2022-11, Vol.33, p.S1463-S1464

2022

Volltextzugriff (PDF)

O-5 Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study

Annals of oncology, 2022-06, Vol.33, p.S380-S381

2022

Volltextzugriff (PDF)

Colchicine Myotoxicity: Case Reports and Literature Review

Pharmacotherapy, 2004-12, Vol.24 (12), p.1784-1792

2004

Volltextzugriff (PDF)

SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Annals of oncology, 2023-06, Vol.34, p.S168-S168

2023

Volltextzugriff (PDF)

EDUCATION, INTELLIGENCE, AND ATTITUDE EXTREMITY

Public opinion quarterly, 2014-12, Vol.78 (4), p.832-858

2014

Volltextzugriff (PDF)

83P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Annals of oncology, 2022-11, Vol.33, p.S1465-S1466

2022

Volltextzugriff (PDF)

67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Annals of oncology, 2022-11, Vol.33, p.S1456-S1456

2022

Volltextzugriff (PDF)

714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Annals of oncology, 2022-09, Vol.33, p.S869-S870

2022

Volltextzugriff (PDF)

Religion, clubs, and emergent social divides

Journal of economic behavior & organization, 2011-09, Vol.80 (1), p.74-87

Makowsky, Michael D.

2011

Volltextzugriff (PDF)

Computer Science Logic: 17th International Workshop, CSL 2003, 12th Annual Conference of the EACSL, and 8th Kurt Gödel Colloquium, KGC 2003, Vienna, Austria, August 25-30, 2003, Proceedings

1, 2003

Volltextzugriff (PDF)

A theory of liberal churches

Mathematical social sciences, 2011, Vol.61 (1), p.41-51, Article 41

Makowsky, Michael D.

2011

Volltextzugriff (PDF)

Contested claims in carpal tunnel surgery: outcome study of worker's compensation factors

The Iowa orthopaedic journal, 1999, Vol.19, p.111-121

1999

Volltextzugriff (PDF)

Feasibility of a self-administered survey to identify primary care patients at risk of medication-related problems

Journal of multidisciplinary healthcare, 2014-01, Vol.7 (default), p.123-127

2014

Volltextzugriff (PDF)

Computer science logic: 19th International Workshop, CSL 2005, 14th Annual Conference of the EACSL, Oxford, UK, August 22-25, 2005, proceedings

2006

Volltextzugriff (PDF)

Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia

The Annals of pharmacotherapy, 2005-07, Vol.39 (7-8), p.1365-1366

2005

Volltextzugriff (PDF)

1 – 25 von 193

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(185)

Publikationsform

Sprache

Englisch
(190)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(88)
Computer Science
(53)
Technology
(53)
Computer Science, Theory & Methods
(48)
Exact Sciences And Technology
(46)
Applied Sciences
(43)
Computer Science; Control Theory; Systems
(43)
Theoretical Computing
(40)
Logical, Boolean And Switching Functions
(37)
Life Sciences & Biomedicine
(33)
Humans
(25)
Female
(16)
Male
(13)
Pharmacists
(13)
Middle Aged
(11)
Social Sciences
(8)
Studies
(8)
Mathematics
(7)
Physical Sciences
(7)
Aged
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer

Cardiovascular safety of sulphonylureas: over 40years of continuous controversy without an answer

How have pharmacists in different practice settings integrated prescribing privileges into practice in Alberta? A qualitative exploration

206TiP SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma

Endogenous Group Formation via Unproductive Costs

169P Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)

166P Outcomes by baseline liver function in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) with or without bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)

CO70 Matching Adjusted Indirect Comparison (MAIC) of Single Tremelimumab Regular Interval Durvalumab (STRIDE) Versus Atezolizumab with Bevacizumab (A+B) for the Treatment of Unresectable Hepatocellular Carcinoma (UHCC)

167P Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

79P Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study

O-5 Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study

Colchicine Myotoxicity: Case Reports and Literature Review

SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

EDUCATION, INTELLIGENCE, AND ATTITUDE EXTREMITY

83P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Religion, clubs, and emergent social divides

Computer Science Logic: 17th International Workshop, CSL 2003, 12th Annual Conference of the EACSL, and 8th Kurt Gödel Colloquium, KGC 2003, Vienna, Austria, August 25-30, 2003, Proceedings

A theory of liberal churches

Contested claims in carpal tunnel surgery: outcome study of worker's compensation factors

Feasibility of a self-administered survey to identify primary care patients at risk of medication-related problems

Computer science logic: 19th International Workshop, CSL 2005, 14th Annual Conference of the EACSL, Oxford, UK, August 22-25, 2005, proceedings

Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia

Suchergebnisse filtern